Credit Suisse analyst James Wicklund says Halliburton continues to be his top pick for the 2017 recovery, despite high expectations, commentary on international activity, and a very active NAM-focused IPO calendar causing the stock to underperform following its earnings report. The analyst believes that holding profitable market share is an "excellent strategy" off the bottom and should drive earnings revisions up over the next few years. He reiterated an Outperform rating on the stock but lowered his price target on the shares to $60 from $62.

Unusual total active option classes on open include: ImmunityBio (IBRX), Halliburton (HAL), Redfin (RDFN), Nokia (NOK), Matterport (MTTR), General Motors (GM), UPS (UPS), Philip Morris (PM), PepsiCo (PEP), and General Electric (GE).

Reports Q1 revenue $5.8B, consensus $5.67B. "Halliburton delivered solid first quarter results that again demonstrated the power of our strategy and the strength of our execution. Activity in North America recovered from fourth-quarter lows, and our international business delivered its 11th consecutive quarter of year-on-year growth," commented Jeff Miller, Chairman, President and CEO. "Our customers' multi-year activity plans across markets and asset types confirms my confidence in the strength and duration of this upcycle. Halliburton demonstrated its commitment to shareholder returns in the first quarter and repurchased $250 million of common stock - a solid start to the year and a good benchmark for our expectations going forward," concluded Miller.